UNIC
SFDR Classification

Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc

Latest NAV
16.9406 USD
Performance YTD

2.77%

Assets Under Management
354m USD
TER
0.15%
ISIN
LU2023678282
Dividend Policy
Capitalisation
Investment Objective

The Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc is a UCITS compliant exchange traded fund that aims to track the MSCI ACWI IMI Disruptive technology ESG Filtered Index. The index aims to represent the performance of companies expected to derive significant revenue from areas like 3D printing, the ‘Internet of Things’, cloud computing, Fintech, digital payments, healthcare, robotics, clean energy and smart grids, and cybersecurity. The index methodology employs a set of key words of theme-related products, services and concepts built using natural language processing and data analysis techniques. These key words help identify relevant companies based on the proportion of revenue that can be linked to the Disruptive Technology theme. Annually, the expression of the high-level index objective and associated sub-themes are reviewed with the consultative input of a thematic industry expert retained by MSCI. The index is filtered based on MSCI ESG Ratings, controversy scores and certain business activities, with final stock weights based on a combined score of three fundamental metrics: 1-year sales growth, Return on Invested Capital, and % sales spent on R&D and Capex. Lyxor ETFs are efficient investment vehicles listed on exchange that offer transparent, liquid and low-cost exposure to the underlying benchmark index.

Target TER is 0.45% but has temporarily been decreased to 0.15% until September 2021.

UNIC
SFDR Classification

Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc

PERFORMANCE

Performance history

Legend:

The figures relating to [past performances / simulated past performances / past performances and simulated past performances] refer or relate to past periods and are not a reliable indicator of future results. This also applies to historical market data.

Product YTD 1M 3M 1Y 3Y 5Y 10Y ALL
Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc ETF 2.77% -2.36% 2.81% 37.55% - - - 73.81%
MSCI ACWI IMI Disruptive Technology ESG Filtered Net Total Return Index Benchmark Index 3.24% -2.35% 2.93% 38.42% - - - 74.95%
Data as of 30/07/2021, Source: Lyxor International Asset Management
Product 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc ETF - - - - - - - - - -
MSCI ACWI IMI Disruptive Technology ESG Filtered Net Total Return Index Benchmark Index - - - - - - - - - -
Data as of 30/07/2021, Source: Lyxor International Asset Management
Product 1Y
Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF - Acc ETF 37.55%
MSCI ACWI IMI Disruptive Technology ESG Filtered Net Total Return Index Benchmark Index 38.42%
Data as of 30/07/2021, Source: Lyxor International Asset Management

NAV History

Date NAV Currency Fund AUM
30/07/2021 16.6938 USD 349m USD
29/07/2021 16.7013 USD 349m USD
28/07/2021 16.7083 USD 349m USD
27/07/2021 16.4279 USD 343m USD
26/07/2021 16.6362 USD 348m USD

Dividend History

This fund does not distribute any dividend.

HOLDINGS

This ETF uses physical replication to track the performance of the index. As such, the holdings of the ETF reflect those of the benchmark index.
You can read more about our approach to replication in our pragmatic guide to replication.

Name Currency Weight Sector Country
PROTHENA CORP PLC USD 1.7% Health Care Ireland
Arcturus Therapeutics Ltd USD 1.53% Health Care United States
DATADOG INC - CLASS A USD 1.46% Information Technology United States
ROCK TENN COMPANY -CL A USD 1.37% Financials United States
CLOUDFLARE INC - CLASS A USD 1.36% Information Technology United States
MIRATI THERAPEUTICS INC USD 1.32% Health Care United States
OBI PHARMA INC TWD 1.28% Health Care Taiwan
Inovio Pharmaceuticals Inc USD 1.2% Health Care United States
AXONICS MODULATION TECHNOLOG USD 1.12% Health Care United States
NOVAVAX INC USD 1.07% Health Care United States
Name Listing Currency Quantity Weight Sector Country
PROTHENA CORP PLC USD 111,087 1.6% Health Care Ireland
DATADOG INC - CLASS A USD 45,103 1.43% Information Technology United States
ROCK TENN COMPANY -CL A USD 279,430 1.38% Financials United States
CLOUDFLARE INC - CLASS A USD 40,080 1.36% Information Technology United States
MIRATI THERAPEUTICS INC USD 28,669 1.32% Health Care United States
OBI PHARMA INC TWD 1.18m 1.31% Health Care Taiwan
Inovio Pharmaceuticals Inc USD 494,677 1.19% Health Care United States
AXONICS MODULATION TECHNOLOG USD 59,178 1.15% Health Care United States
INTELLIA THERAPEUTICS INC USD 26,010 1.06% Health Care United States
SUNNOVA ENERGY INTERNATIONAL USD 95,070 1.04% Utilities United States

This funds does not use sec/lending

Index Information

Full Name MSCI ACWI IMI Disruptive Technology ESG Filtered Net Total Return Index
Index Type Performance
Index Bloomberg Ticker MXACDSRT
Index Currency USD
Number of Index Components 187
Further Information www.msci.com
Dividend Yield (%) 0.48
Data as of 29/07/2021

Index Composition Breakdown

Currency Breakdown

USD 74.12%
EUR 8.27%
TWD 3.6%
CHF 3.26%
Others 3.01%
HKD 1.8%
CAD 1.73%
CNY 1.53%
JPY 1.44%
SEK 1.24%

Sector Breakdown

Information Technology 44.52%
Health Care 39.29%
Industrials 6.75%
Utilities 3.02%
Communication Services 2.23%
Financials 2.05%
Energy 1.18%
Consumer Discretionary 0.58%
Materials 0.39%

Countries Breakdown

United States 71.72%
China 4.1%
Germany 3.76%
Taiwan 3.6%
Switzerland 3.26%
Canada 1.73%
Ireland 1.7%
France 1.59%
Japan 1.44%
Sweden 1.24%
Australia 1%
Netherlands 0.94%
United Kingdom 0.72%
Belgium 0.68%
Denmark 0.58%
Puerto Rico 0.57%
South Korea 0.5%
Spain 0.44%
Italy 0.22%
Thailand 0.11%
Hong Kong 0.11%
Data as of 03/08/2021, Source: Lyxor International Asset Management

CHARACTERISTICS

Main Fund Characteristics

ISIN LU2023678282
UCITS Yes
Share Class Currency USD
Assets Under Management 354.1m USD
Total Expense Ratio 0.15%
Dividend Treatment Capitalisation
EU-SD Status Out of Scope
Fund Type SICAV
Domicile Luxembourg
Replication Method Direct (Physical)
Sampling No
Securities Lending No
Umbrella AUM 14,640m USD
Portfolio Managers Raphaël Dieterlen, Salah BENAISSSA
Financial Year End 31/10/2021
Inception Date 02/03/2020
Minimum Investment 1 Share
SFDR Classification 8

DISCLAIMER: This fund includes a risk of capital loss. Investors therefore may not recover all or part of their initial investment. The redemption value of this fund may be less than the amount initially invested. In a worst case scenario, investors could sustain the loss of their entire investment. Be sure to read carefully the Key Investor Information document, and the “risk factors” section of a fund’s performance to better understand the risks involved.

Trading Information

Exchange Ticker Bloomberg Listing Currency Currency Hedged Listing Date Dividend Policy ADV 3M ISIN Fund AUM in CCY
Euronext UNIC FP EUR - 21/04/2020 Capitalisation 99,864EUR LU2023678282 294m EUR
Xetra DRUP GY EUR - 30/04/2020 Capitalisation 361,107EUR LU2023678282 294m EUR
Borsa Italiana UNIC IM EUR - 30/04/2020 Capitalisation 802,141EUR LU2023678282 294m EUR
BMV UNICN MM MXN - 18/05/2021 Capitalisation - LU2023678282 6,929m MXN
LSE UNIC LN USD - 30/04/2020 Capitalisation 70,031USD LU2023678282 349m USD
LSE DTEC LN GBP - 30/04/2020 Capitalisation 80,661GBP LU2023678282 251m GBP
SIX Swiss Ex QBIT SW CHF - 23/04/2020 Capitalisation 122,665CHF LU2023678282 316m CHF
*Related Shareclasses

Market Makers

Flow Traders
Optiver
Société Générale
Data provided by relevant exchanges

Passporting Information

UK
Spain
France
Germany
Belgium
Netherlands
Italy
Switzerland
Luxembourg
Austria
Sweden
Finland
Norway
Denmark
Korea
Data as of 30/07/2021, Source: Lyxor International Asset Management

NEWS

Blog
15/04/2021

Blog Disruptive Technology vlog: invest in tomorrow’s giants, today

Notice to Shareholders
28/01/2021

Notice to Shareholders Annual general meeting of Lyxor Index Fund

Blog
10/06/2020

Blog Disruptive Technology in a post-Covid world